玮俊生物科技(00660.HK) 发盈警,预料截至2024年6月30日止年度将录得综合净亏损介乎5,700万至6,200万元,对比2023年同期净亏损为约1,000万元,净亏损增加归因于期内毛利减少,以及录得物业、厂房及设备减值亏损。(gc/a)(港股报价延迟最少十五分钟。)
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/02/29 | 中期业绩 | 无派息 |
2023/09/29 | 末期业绩 | 无派息 |
2023/02/28 | 中期业绩 | 无派息 |
2023/01/10 | 特别业绩 | 合并:10股合并为1股 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.